The USPTO Office of the Chief Economist has releases a comprehensive set of patent litigation data files for public use. The Patent Litigation Dataset has been updated as of December…
The FDA Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations, is the definitive source to link drugs with the patents that protect them. Over the years we’ve had…
This article was originally published by Syed Sauban Ghani in Eclética Química under a Creative Commons license. ABSTRACT As scientific community worldwide is publishing a huge number of research articles…
This article was originally published by Mohammed M. Alshehri and Mahmoud M. E. Mudawi in the Journal of Pharmaceutical Research International under the terms of the Creative Commons Attribution License.…
Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of challengers of each patent is also increasing. Why might this…
Check out the latest issue of Lab Manager where I discuss my interest in informatics, the complexities of informatics for today’s scientists, and some of the tools available. https://www.labmanager.com/ask-the-expert/trends-in-informatics-22895
In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day Patent Challenge Exclusivity Expirations Anticipate…
Let DrugPatentWatch build custom dashboards and reports to take the load off of your team. We can ensure the production of accurate, objective, and timely intelligence to help you quickly…
Drug repurposing patent documents vs peer review: patent information comes more than 600 days earlier on average
0
This article was originally published by Hermann Mucke & Peter Mucke in Future Drug Discovery under a Attribution-NonCommercial-NoDerivatives 4.0 Unported License. https://doi.org/10.4155/fdd-2020-0001. Drug developers require access to scientific information in…
In a recent court ruling, the U.S. Court of Appeals for the Federal Circuit (CAFC) denied a petition to rehear arguments regarding the invalidity of patent claims containing the phrase…
